fda update on semaglutide New Weight Loss Medication Wegovy™ Approved by the FDA Warns on Certain Forms

Cancer 97 , 10151024 (2003)

2026;9(5):e2612133

Current medical consensus suggests that most patients will require continued pharmacotherapy to maintain weight loss and metabolic improvements

A study published in the Proceedings of the National Academy of Sciences found that aging is associated with a 47% decrease in the catalytic subunit (GCLC) and a 52% decrease in the modulatory subunit (GCLM) of glutamate-cysteine ligase, the rate-limiting enzyme for glutathione production

This approval represents a meaningful shift in obesity treatment, expanding options beyond injectable therapies and introducing a more convenient, patient-centric approach that may support earlier intervention and long-term adherence